Abstract | BACKGROUND: METHODS: A systematic literature search was conducted in MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, and Clinical Trials.gov to identify randomized controlled trials (RCTs) comparing the effect of cinacalcet relative to standard treatment on CKD-MBD surrogate markers and clinical outcomes. Random-effect models were used to compute the weighted mean difference for continuous variables and the risk ratio for binary variables. RESULTS: CONCLUSIONS:
|
Authors | Primploy Greeviroj, Thidarat Kitrungphaiboon, Pisut Katavetin, Kearkiat Praditpornsilpa, Somchai Eiam-Ong, Bertrand L Jaber, Paweena Susantitaphong |
Journal | Nephron
(Nephron)
Vol. 139
Issue 3
Pg. 197-210
( 2018)
ISSN: 2235-3186 [Electronic] Switzerland |
PMID | 29514156
(Publication Type: Journal Article, Meta-Analysis, Systematic Review)
|
Copyright | © 2018 S. Karger AG, Basel. |
Chemical References |
- Calcimimetic Agents
- FGF23 protein, human
- Minerals
- Fibroblast Growth Factor-23
- Cinacalcet
|
Topics |
- Calcimimetic Agents
(therapeutic use)
- Chronic Kidney Disease-Mineral and Bone Disorder
(drug therapy)
- Cinacalcet
(therapeutic use)
- Fibroblast Growth Factor-23
- Humans
- Minerals
(metabolism)
- Randomized Controlled Trials as Topic
|